Sandgaard Capital

Sandgaard Capital is a public and private equity investment group and family office founded by @SandgaardThomas.

[Kyle D. Henderson @HendersonKyleD]

How are Private Equity firms adapting to tougher financing, tougher exits, and increasing regulatory scrutiny?

In my latest post, I explore what 2025 looks like for PE — where risk meets opportunity, and how discipline & operational focus are becoming essential.

Read here ⬇️
https://t.co/rxzdBfzXPF

[Sandgaard Capital @SandgaardCap]

Thomas Sandgaard, CEO of Sandgaard Capital, shares his perspective on the state of the economy in 2025 — where resilience meets uncertainty, and opportunity emerges.

Read his full insights here: 
https://t.co/S4q7s8QWom

#Economy2025 #MarketOutlook #GlobalEconomy #BusinessTrends #EconomicInsights #ExecutiveInsights #LeadershipPerspective #CEOInsights #ThoughtLeadership

[Sandgaard Capital @SandgaardCap]

📢 Leadership Update at Zynex Inc (NASDAQ: ZYXI)

We’re excited to share that Steven Dyson has officially taken the helm as CEO of Zynex, joined by a strengthened executive team:

- Vikram Bajaj – Chief Financial Officer (finance & strategy leader with 20+ years in medtech)

- John T. Bibb – Chief Legal Officer (legal, HR & compliance expertise across major healthcare firms)

- Ajay Gopal – EVP of Sales (track record of commercial growth and expanding patient access)

- Agnes Powell – VP of Billing (20 years of experience in revenue cycle and managed care operations)

Board Chairman Thomas Sandgaard expressed confidence in this proven group of leaders to “take Zynex to new levels of success.”

CEO Steven Dyson added: “We have the right team in place to deliver excellent results while renewing our commitment to integrity and improving quality of life for patients suffering from pain and illness.”

📈 Zynex shares rose nearly 6% following the announcement.

At Sandgaard Capital, we remain committed to supporting Zynex as it enters this next phase of growth and transformation.

Click here to learn more: https://t.co/CVUUceeU4f

#Zynex #Leadership #NASDAQ $ZYXI #MedicalTechnology #Growth

[Proactive @proactive_x]

$ZYXI Zynex welcomes Steve Dyson as CEO, adds to leadership team https://t.co/nrb8ndLtJF @ZynexMedical #ZYXI

[Proactive @proactive_x]

Zynex appoints Steven Dyson as CEO; founder Thomas Sandgaard moves to Chairman role to steer vision https://t.co/9zonKQBQ80 #proactiveinvestors #zynexinc #nasdaq #zyxi #healthcare

[Sandgaard Capital @SandgaardCap]

Zynex, Inc. (Nasdaq: ZYXI) appoints Steven Dyson as CEO; founder Thomas Sandgaard transitions to the Chairman role to steer the vision.

Zynex Inc. announced a significant leadership transition as Founder and longtime CEO Thomas Sandgaard steps into the role of Chairman of the Board and Chair of the Technology Committee, while Steven Dyson assumes the position of Chief Executive Officer.

In a joint conversation with Steve Darling from Proactive, Sandgaard explained that this move marks a strategic evolution for Zynex as it adapts to a dynamic healthcare environment. Sandgaard, who founded the company in 1996 and led it from inception to Nasdaq listing, emphasized that Dyson brings the leadership, experience, and global perspective necessary to take Zynex to the next level.

Steven Dyson joins Zynex with more than 25 years of international leadership experience in the medical technology and healthcare sectors. Most notably, Dyson served as a senior executive at Apax Partners, a leading private equity firm (~$80Bn AUM) where he played key roles in scaling and exiting high-profile healthcare companies across Europe, North America, and Asia. His track record includes transformative roles at KCI, Rodenstock, Unilabs, Healthium Medtech, and Neuraxpharm, giving him a robust foundation in growth strategy, operational optimization, and global expansion.

At Zynex, Dyson will lead the company through a refined strategic focus, particularly targeting a more optimized payer mix, streamlined operations, and expanded market penetration in non-invasive pain management and medical diagnostic devices.

As Chairman, Sandgaard will continue to shape Zynex’s product and technology pipeline, ensuring its R&D efforts remain competitive and aligned with evolving healthcare trends, especially in pain relief solutions and wearable diagnostics.

This leadership evolution underscores Zynex’s commitment to growth, modernization, and value creation, with a steady hand at the helm and a fresh operational engine poised to accelerate the company’s trajectory in the medtech space.

Watch the full interview here: https://t.co/uJ2svxtgTJ

[Proactive USA @proactive_NA]

Zynex CEO Thomas Sandgaard discusses leadership transition - ICYMI @ZynexMedical #NASDAQ #ZYXI https://t.co/OK8jTzI2Gw

[Sandgaard Capital @SandgaardCap]

📣 Big news from Zynex Medical and Zynex Monitoring Solutions (Nasdaq: ZYXI)

After nearly three decades at the helm, founder Thomas Sandgaard is transitioning from CEO to Chairman of the Board, ushering in a new chapter for the company. 🚀

We’re thrilled to welcome Steven Dyson as Zynex's new Chief Executive Officer — a globally respected healthcare leader with a proven track record at Apax (global private equity firm with ~$80Bn AUM), where he scaled some of the world’s most successful medtech and pharma businesses, including KCI, Unilabs, Rodenstock, and Neuraxpharm.

With Steven’s leadership and Thomas’s continued guidance as Chair of the Technology Committee, Zynex is poised for renewed focus, performance, and innovation in non-invasive pain management and diagnostic technology.
This is a pivotal step forward in aligning our operations, optimizing our payer mix, and accelerating our long-term growth.

📈 The next era at Zynex starts now!

[Proactive @proactive_x]

Zynex appoints Steven Dyson as CEO, founder Thomas Sandgaard transitions to Chairman role https://t.co/MHcvgay2Xl #proactiveinvestors #zynexinc #nasdaq #zyxi #healthcare #ThomasSandgaard

[Sandgaard Capital @SandgaardCap]

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Steven Dyson as Chief Executive Officer. His employment will begin on August 18, 2025.

Thomas Sandgaard, Founder of Zynex and Chairman of the Board since the company's inception in 1996, will remain actively involved as Chairman and Chair of the Board's Technology Committee.

Steven brings over 25 years of experience in the medical technology sector, primarily through his leadership at Apax, a global private equity firm. He has played a key role in acquiring, growing, and exiting numerous healthcare and medtech companies around the world. His board and transaction experience includes companies such as KCI (San Antonio, TX), Rodenstock (Germany), Healthium Medtech (India), Unilabs (Switzerland), and Neuraxpharm (Spain).

Steven will operate from the Zynex headquarters in Englewood, Colorado, while maintaining a residence in London, England. He holds a B.A. from Oxford University and a Ph.D. from Cambridge University.

"I am excited to step back from day-to-day operations and continue contributing as Chairman," said Thomas Sandgaard. "Steven brings deep expertise and a proven track record in the medical sector. His leadership will be instrumental as we refocus our business strategy toward a more optimized payer mix and work to return Zynex to a strong growth trajectory."

Newly appointed CEO Steven Dyson added, "I'm honored to join the Zynex team at this exciting time in the Company's history and to have the opportunity to lead the Company back to a strong growth trajectory. Zynex's strong foundation, built by Thomas over many years, provides an excellent platform to deliver exceptional value for all our stakeholders."

Learn more via the Financial Times: https://t.co/k0Ohl823BA

Zynex Medical | Zynex Monitoring Solutions | Nasdaq $ZYXI | https://t.co/42WseZSDeU

[Sandgaard Capital @SandgaardCap]

🚨 Zynex (NASDAQ: ZYXI) Secures UK Patent for Non-Invasive Sepsis Monitoring Technology 🚨

Zynex Monitoring Solutions has been awarded a UK patent for its groundbreaking multiparameter, non-invasive sepsis monitor — a device designed to help clinicians detect sepsis earlier by continuously tracking multiple vital signs.

🦠 Sepsis affects over 1.7 million people annually in the U.S. and is responsible for 1 in 3 hospital deaths.

📊 Early detection remains one of the biggest challenges in treating this life-threatening condition.

🌍 Zynex’s technology supports global efforts like the Surviving Sepsis Campaign to reduce sepsis-related mortality.

CEO Thomas Sandgaard stated:

“Sepsis is a global health crisis. This technology has the potential to drastically reduce deaths by delivering real-time, non-invasive data to clinicians.”

Donald Gregg, President of Zynex Monitoring Solutions, added:

“We believe we can significantly contribute to earlier detection and better outcomes.”

Zynex continues to lead innovation in critical care monitoring with a focus on improving patient lives.

Read more here: https://t.co/Gm8ptxArvz

#Zynex #ZYXI #HealthcareInnovation #SepsisAwareness #MedicalDevices #NonInvasiveTech #PatientCare #UKPatent #NASDAQ #CriticalCare

[Proactive USA @proactive_NA]

Zynex awarded UK patent for non-invasive sepsis monitoring technology @ZynexMedical #NASDAQ #ZYXI https://t.co/9EQ1E0phf9

[Sandgaard Capital @SandgaardCap]

Big News: @ZynexMedical and @MellingMedical Are Expanding Access to Non-Invasive Pain Relief for Veterans and Military Personnel! 💥

Two leaders in healthcare have joined forces to bring innovative, non-pharmacological pain management solutions to the entire federal healthcare system. 🙌

What’s happening:
🤝 Zynex Medical is partnering with MellingMedical, a Service-Disabled Veteran-Owned Small Business (SDVOSB)

📦 Zynex’s breakthrough devices, like the NexWave (combining IFC, TENS, NMES) will now be available to:
- 172 VA Medical Centers
- 1,138 VA Outpatient Clinics
- 95 DoD Medical Facilities

7 VA Consolidated Mail Outpatient Pharmacies (CMOPs)
- Why it matters:
- Offers non-invasive alternatives to opioids
- Helps reduce dependency on pain meds while improving outcomes
- Includes electrotherapy devices, bracing solutions, and rehab tools for chronic pain and functional disabilities
- “This is about delivering innovation where it’s needed most—serving those who’ve served our country,” said Zynex Founder & CEO, @SandgaardThomas.

👏 A huge step forward in federal pain care, and a powerful reminder that healing doesn’t have to come in a pill bottle.

[MellingMedical @MellingMedical]

Announcing the newest addition to our portfolio of companies who share our dedication to providing the best in medical care to America's veterans, active duty service members and their families. Welcome @ZynexMedical!
#VetHealth
https://t.co/E9uu8kqlQr

[Sandgaard Capital @SandgaardCap]

🚨 Major update from Zynex Monitoring Solutions (NASDAQ: $ZYXI): The company has officially submitted its NiCO™ non-invasive CO-Oximeter to the FDA for clearance.

💡 Why this matters:
NiCO™ is a breakthrough medical device designed to address long-standing flaws in traditional pulse oximeters. It uses proprietary laser technology—rather than outdated LEDs—to provide accurate oxygen readings across all skin tones, even with nail polish. Critically, it also detects carbon monoxide poisoning non-invasively and instantly, a capability that existing devices lack.

🗣️ CEO Thomas Sandgaard explained:
“This device can make a very significant and very meaningful difference... It provides instant information, even in cases of carbon monoxide poisoning, and reads accurately regardless of dark skin or even nail polish.”

🩺 Traditional pulse oximeters have seen little innovation in decades and have shown major blind spots—especially for patients with darker skin, as highlighted during the COVID-19 pandemic. NiCO™ aims to solve that, offering hospitals and clinicians more reliable, equitable data.

🎯 The initial target market is hospitals—part of a $1B+ global opportunity—but the broader implications for patient care and health equity are even more far-reaching.

🗓️ Zynex expects a response from the FDA in approximately 6 months and is preparing for commercial launch shortly thereafter.

🔗 Read the full article via Proactive Investors:
https://t.co/E18OREMpce

[Sandgaard Capital @SandgaardCap]

Big News from Zynex Monitoring Solutions! $ZYXI

Zynex has officially submitted its FDA 510(k) application for the NiCO™ laser-based pulse oximeter — a next-gen innovation that could redefine accuracy in oxygen monitoring.

🔬 Unlike traditional red-infrared tech, NiCO™ uses laser light to potentially detect oxygen saturation and pulse rate more reliably — especially in patients with poor circulation, dark skin pigmentation, or low perfusion.

Why does this matter?
➡️ Lives depend on precision.
➡️ Millions of patients are monitored daily with oximeters.
➡️ Greater accuracy = better outcomes in critical care, surgery, and recovery.

This marks a bold step forward in Zynex’s commitment to patient-first innovation. 🚀 Zynex is not just treating pain — they are pushing boundaries in non-invasive monitoring.

📈 Stay tuned as we await feedback from the FDA. If cleared, NiCO™ could become a game-changer in clinical settings across the country.

Click the following link to learn more: https://t.co/0IVMdY8KlQ

#Zynex #MedicalTech #FDA #PulseOximeter #InnovationInHealthcare #LaserTech #PatientSafety #NiCO #ZynexStrong #HealthTech #MedDevice #FDAApprovalPending

[Proactive USA @proactive_NA]

Zynex submits FDA application for NiCO laser pulse oximeter @ZynexMedical #NASDAQ #ZYXI https://t.co/xBkHinjWRt

[Sandgaard Capital @SandgaardCap]

🏆 Danish Champions! A Historic Moment for the Odense Bulldogs!🏆

Today, Sandgaard Capital's Odense Bulldogs reached the pinnacle of Danish professional hockey and are now Danish Champions!

"We are honored to own and invest in this remarkable professional hockey team as they etch their names into history. This victory is a milestone that will inspire future generations of Bulldogs — and it’s only the beginning of even greater things to come." - @SandgaardThomas

"Congratulations to the entire organization, the fans, and the city of Odense! Let’s savor this moment — Champions of Denmark!" - Martin Sandgaard

"Winning the national championship isn’t just about lifting a trophy — it’s a testament to the years of hard work, resilience, and belief that define this incredible team. It represents the heart of Odense, the spirit of competition, and the pride of an entire community." - @HendersonKyleD

[Proactive @proactive_x]

Zynex Medical champions noninvasive, non-addictive pain management with NexWave @ZynexMedical #NASDAQ #ZYXI https://t.co/OdusCWWcqG

[Sandgaard Foundation @SandgaardFnd]

🚨 How to Respond to an Opioid Overdose 🚨

Every second counts. Here’s what to do if someone is experiencing an opioid overdose — you could save a life.

SIGNS OF OVERDOSE 🔍:
-💧 Pale, clammy skin. Blue or purple lips/nails.
-🫁 Slow or no breathing.
-💔 Slowed heartbeat or unresponsive.
-😴 Unable to wake or speak.

TAKE THESE STEPS IMMEDIATELY🆘:
Call 911 📞
– Stay on the line. Tell them it’s an overdose.

Administer Narcan (Naloxone) 💉
– Use the nasal spray version if available.
– Tilt the person’s head back and spray 1 dose into one nostril.
– If no response in 2-3 minutes, give a second dose in the other nostril.

Perform Rescue Breathing/CPR 🫁
– If trained, give rescue breaths or chest compressions if they’re not breathing.

Stay with them ⏱️
– Keep the person on their side (recovery position) if they’re breathing.
– Stay until help arrives. More Narcan may be needed.

Don’t be afraid ❤️
– Many states have Good Samaritan laws to protect you when helping in an overdose.

🙌 Narcan is safe, easy to use, and available without a prescription in many places. Carry it. Know it. Use it.

#EndOverdose #OpioidCrisis #NarcanSavesLives #HarmReduction #OverdoseAwareness #BeTheDifference

[Sandgaard Capital @SandgaardCap]

Zynex Expands Medical Innovation Portfolio! ✨

Zynex Inc. (Nasdaq: ZYXI) is breaking barriers with its cutting-edge NiCO laser pulse oximeter, designed for unparalleled precision in measuring blood oxygen levels.

Following successful trials at Duke University, the device addresses inaccuracies in traditional oximeters, particularly for individuals with darker skin tones, paving the way for equitable healthcare solutions.

The company eyes FDA submission by June and continues its mission to revolutionize pain management with products like the NexWave and TensWave devices.

✨Big news: Zynex recently partnered with Veterans Affairs Medical Centers, opening doors to serve over 9 million veterans with advanced, non-opioid pain management solutions.

Stay tuned for updates as Zynex shapes the future of healthcare!

Read the entire article via the following link to learn more: https://t.co/rnq32lOvrf

#Innovation #Zynex #HealthcareEquity #PulseOximetry #FDAApproval